TW202320804A - Akr1c3活化的dna烷化劑及其醫藥用途 - Google Patents

Akr1c3活化的dna烷化劑及其醫藥用途 Download PDF

Info

Publication number
TW202320804A
TW202320804A TW111142123A TW111142123A TW202320804A TW 202320804 A TW202320804 A TW 202320804A TW 111142123 A TW111142123 A TW 111142123A TW 111142123 A TW111142123 A TW 111142123A TW 202320804 A TW202320804 A TW 202320804A
Authority
TW
Taiwan
Prior art keywords
compound
group
cancer
days
tumor
Prior art date
Application number
TW111142123A
Other languages
English (en)
Chinese (zh)
Inventor
李安蓉
段建新
繁英 孟
齊天陽
孟滕
張夢雲
Original Assignee
大陸商深圳艾欣達偉醫藥科技有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 大陸商深圳艾欣達偉醫藥科技有限公司 filed Critical 大陸商深圳艾欣達偉醫藥科技有限公司
Publication of TW202320804A publication Critical patent/TW202320804A/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C201/00—Preparation of esters of nitric or nitrous acid or of compounds containing nitro or nitroso groups bound to a carbon skeleton
    • C07C201/06—Preparation of nitro compounds
    • C07C201/12—Preparation of nitro compounds by reactions not involving the formation of nitro groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/27—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups
    • C07C205/35—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups having nitro groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/27—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups
    • C07C205/35—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups having nitro groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C205/36—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups having nitro groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton to carbon atoms of the same non-condensed six-membered aromatic ring or to carbon atoms of six-membered aromatic rings being part of the same condensed ring system
    • C07C205/38—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups having nitro groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton to carbon atoms of the same non-condensed six-membered aromatic ring or to carbon atoms of six-membered aromatic rings being part of the same condensed ring system the oxygen atom of at least one of the etherified hydroxy groups being further bound to a carbon atom of a six-membered aromatic ring, e.g. nitrodiphenyl ethers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/564—Three-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
TW111142123A 2021-11-05 2022-11-04 Akr1c3活化的dna烷化劑及其醫藥用途 TW202320804A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
WOPCT/CN2021/129077 2021-11-05
PCT/CN2021/129077 WO2023077452A1 (zh) 2021-11-05 2021-11-05 Akr1c3活化的dna烷化剂及其医药用途

Publications (1)

Publication Number Publication Date
TW202320804A true TW202320804A (zh) 2023-06-01

Family

ID=86240506

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111142123A TW202320804A (zh) 2021-11-05 2022-11-04 Akr1c3活化的dna烷化劑及其醫藥用途

Country Status (6)

Country Link
EP (1) EP4428138A4 (https=)
JP (1) JP2024539385A (https=)
KR (1) KR20240110013A (https=)
CN (1) CN118201940A (https=)
TW (1) TW202320804A (https=)
WO (1) WO2023077452A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114106042B (zh) * 2021-11-12 2022-09-16 深圳艾欣达伟医药科技有限公司 一种氘代化合物及其制备方法和应用
KR20260009356A (ko) 2023-05-11 2026-01-19 아센타위츠 파마슈티컬즈 리미티드 주사액 제제 및 이의 제조 방법, 및 상용성 약액 및 이의 제조 방법
WO2025140580A1 (zh) * 2023-12-28 2025-07-03 深圳艾欣达伟医药科技有限公司 化合物晶型

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI674258B (zh) * 2015-03-10 2019-10-11 大陸商深圳艾欣達偉醫藥科技有限公司 Ｄｎａ烷化劑
WO2016161342A2 (en) * 2015-04-02 2016-10-06 Threshold Pharmaceuticals, Inc. Nitrobenzyl derivatives of anti-cancer agents
EP3390415B1 (en) * 2015-11-16 2020-02-26 Obi Pharma, Inc. (r)- and (s)-1-(3-(3-n,n-dimethylaminocarbonyl)phenoxyl-4-nitrophenyl)-1-ethyl-n,n'-bis (ethylene)phosphoramidate, compositions and methods for their use and preparation
WO2020228685A1 (zh) * 2019-05-13 2020-11-19 深圳艾欣达伟医药科技有限公司 含氟化合物及抗癌医药用途
US20220387345A1 (en) * 2019-11-01 2022-12-08 Ascentawits Pharmaceuticals, Ltd. Anti-cancer compounds acting as non-pgp substrate
TWI837402B (zh) * 2019-12-20 2024-04-01 大陸商深圳艾欣達偉醫藥科技有限公司 含氟化合物、含氟化合物之製備方法及其抗癌醫藥用途

Also Published As

Publication number Publication date
CN118201940A (zh) 2024-06-14
EP4428138A1 (en) 2024-09-11
WO2023077452A1 (zh) 2023-05-11
EP4428138A4 (en) 2025-08-27
JP2024539385A (ja) 2024-10-28
KR20240110013A (ko) 2024-07-12

Similar Documents

Publication Publication Date Title
TW202320804A (zh) Akr1c3活化的dna烷化劑及其醫藥用途
US20230339991A1 (en) Hypoxia-activated dna alkylating agent and medical use thereof
TWI725488B (zh) Bcl-2抑制劑與化療藥的組合產品及其在預防及/或治療疾病中的用途
JP2009538317A (ja) 癌治療のための置換ジアリールウレアを用いた薬物の組み合わせ
CN110088210A (zh) 与酪氨酸激酶抑制剂结合使用的癌细胞增敏剂和增敏方法
Banerjee et al. X-ray crystallography-guided design, antitumor efficacy, and QSAR analysis of metabolically stable cyclopenta-pyrimidinyl dihydroquinoxalinone as a potent tubulin polymerization inhibitor
TW200811185A (en) Fused pyrimidones and thiopyrimidones, and uses thereof
US20230226198A1 (en) Artemisinin Derivatives
Lu et al. Synthesis and preliminary evaluation of 18F-icotinib for EGFR-targeted PET imaging of lung cancer
CN112533610B (zh) 用于治疗腺样囊性癌的包含双氟烷基-1,4-苯并二氮杂䓬酮化合物的组合物
EP3763390A1 (en) Artemisinin derivatives
WO2026037438A1 (zh) 一种抑制剂化合物及应用和治疗癌症的药物
Ghosh et al. Vincristine enhances the efficacy of MEK inhibitors in preclinical models of KRAS-mutant colorectal cancer
WO2025088087A1 (en) A pyrido-thieno-pyrimidin derivative as alc1 inhibitor for use in the treatment of homologous recombination deficiency (hrd) cancers
EP4495121A1 (en) Camptothecin derivatives that bind to ddx5 protein and prodrugs thereof
EP4726059A1 (en) Correlation of akr1c3 enzyme expression level with kras mutation, and medical use
WO2023014882A1 (en) 2,4 dnp and prodrugs thereof for treatment of cancer
Sun et al. Novel Carbohydrate-substituted Indazole Derivatives Targeting SGLT1 Enhance the Efficacy of Receptor Tyrosine Kinase Inhibitors in Cancer Therapy
TW202547457A (zh) 二氫呋喃并[3,4-f]喹唑啉類化合物、其製備方法及其在醫藥上的應用
Shah et al. Exploring the Anticancer Activity, Molecular Docking and Density Functional Theory Analysis of α‐Naphthalene Acetic Acid Derivatives
Yan et al. Afatinib for a non-small cell lung cancer patient in hemodialysis: A case report and literature review
TW202523322A (zh) 吉西他濱抗癌衍生物及其抗癌醫藥用途和製備方法
AU2024367467A1 (en) A pyrido-thieno-pyrimidin derivative as alc1 inhibitor for use in the treatment of homologous recombination deficiency (hrd) cancers
CN121108109A (zh) 一种靶向alk蛋白的protac化合物及其抗肿瘤应用
Burenkova et al. Design of BET Inhibitor Prodrugs with Superior Efficacy and Devoid of Systemic Toxicities